
Norvasc
Amlodipine Besylate
- SKU
- 58151-353
- UPC
- 0358151354771
- Mfr
- Viatris Specialty LLC
90 tablet in 1 bottle
$1,057.99
Price for one pack
Prescription required. Upload your prescription at checkout or email it to us after ordering. We ship once a pharmacist has checked it. How it works
1 ) o NORVASC is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. 1 Hypertension NORVASC ® is indicated for the treatment of hypertension, to lower blood pressure.
- Strength
- Amlodipine Besylate 2.5 mg/1
- Unit of measure
- Per 1 tablet
- Dosage form
- Tablet
- Route
- Oral
Pharmacologic class
- Calcium Channel AntagonistsMechanism
- Calcium Channel BlockerEstablished class
- Cytochrome P450 3A InhibitorsMechanism
- Dihydropyridine Calcium Channel BlockerEstablished class
- DihydropyridinesChemical structure
- Brand name
- Norvasc
- Generic name
- Amlodipine Besylate
- Manufacturer
- Viatris Specialty LLC
- Product NDC (SKU)
- 58151-353
- UPC
- 0358151354771
- Active ingredients
- Amlodipine Besylate 2.5 mg/1
- Unit of measure
- Per 1 tablet
- Dosage form
- Tablet
- Route
- Oral
- DEA schedule
- Not controlled
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- NDA
- Application number
- NDA019787
- Marketed since
- November 12, 2024
- Label revised
- February 15, 2023
| Package NDC | Description |
|---|---|
| 58151-353-77 | 90 TABLET in 1 BOTTLE |
Reading this NDC
58151-353-77
- 01Labeler code
- Viatris Specialty LLC
- 02Product code
- Norvasc, tablet
- 03Package code
- 90 tablet in 1 bottle
Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow‑channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels.
Amlodipine inhibits calcium ion influx across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Negative inotropic effects can be detected in vitro but such effects have not been seen in intact animals at therapeutic doses. Serum calcium concentration is not affected by amlodipine. Within the physiologic pH range, amlodipine is an ionized compound (pKa=8.6), and its kinetic interaction with the calcium channel receptor is characterized by a gradual rate of association and dissociation with the receptor binding site, resulting in a gradual onset of effect.
Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure. The precise mechanisms by which amlodipine relieves angina have not been fully delineated, but are thought to include the following: Exertional Angina: In patients with exertional angina, NORVASC reduces the total peripheral resistance (afterload) against which the heart works and reduces the rate pressure product, and thus myocardial oxygen demand, at any given level of exercise.
Vasospastic Angina: NORVASC has been demonstrated to block constriction and restore blood flow in coronary arteries and arterioles in response to calcium, potassium epinephrine, serotonin, and thromboxane A2 analog in experimental animal models and in human coronary vessels in vitro. This inhibition of coronary spasm is responsible for the effectiveness of NORVASC in vasospastic (Prinzmetal’s or variant) angina.
NORVASC is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of:
- Hypertension
o NORVASC is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
- Coronary Artery Disease
o Chronic Stable Angina o Vasospastic Angina (Prinzmetal’s or Variant Angina) o Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40%
Hypertension
NORVASC ® is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including NORVASC. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.
Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits.
The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit.
Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. NORVASC may be used alone or in combination with other antihypertensive agents.
Coronary Artery Disease (CAD) Chronic Stable Angina
NORVASC is indicated for the symptomatic treatment of chronic stable angina. NORVASC may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal’s or Variant Angina) NORVASC is indicated for the treatment of confirmed or suspected vasospastic angina. NORVASC may be used as monotherapy or in combination with other antianginal agents.
Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%, NORVASC is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure.
Read before you order

Heart health · 2 min read
Blood pressure medicines explained: ACE inhibitors, ARBs, amlodipine and more
How lisinopril, losartan, amlodipine, hydrochlorothiazide and metoprolol lower blood pressure, and their most common side effects.

Heart health · 2 min read
Statins and cholesterol: how atorvastatin protects your heart
How statins lower LDL cholesterol, who benefits, the truth about muscle aches and what to avoid while taking atorvastatin.

Heart health · 2 min read
Taking apixaban safely: a guide to blood thinners
Why apixaban is prescribed, how to take it twice a day, bleeding signs to watch for and medicines to avoid.
More in Cardiac
View all
Generic · Tablet
Amlodipine Besylate
Amlodipine Besylate 10 mg/1
- SKU
- 67046-1157
- Mfr
- Coupler LLC
From $4.99Min. 61 packs

Generic · Tablet
Amlodipine Besylate
Amlodipine Besylate 10 mg/1
- SKU
- 67296-2297
- Mfr
- Redpharm Drug
From $4.99Min. 61 packs

Generic · Tablet
Atorvastatin Calcium
Atorvastatin Calcium Trihydrate 20 mg/1
- SKU
- 67046-1403
- Mfr
- Coupler LLC
From $4.99Min. 61 packs

Generic · Tablet
Atorvastatin Calcium
Atorvastatin Calcium Trihydrate 10 mg/1
- SKU
- 67046-1677
- Mfr
- Coupler LLC
From $4.99Min. 61 packs